Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed unresectable or metastatic hepatocellular carcinoma not amenable to combined radiotherapy and chemotherapy or orthotopic liver transplantation
• Measurable disease, defined as at least 1 lesion that can be accurately measured in at least 1 dimension as at least 20 mm
• Evidence of disease progression by serial imaging or biochemical evidence of a rising alpha-fetoprotein by serial testing
• No history of brain or other CNS metastases not amenable to local therapy
• * Locally treatable CNS lesions (i.e., lesions treatable with surgery or radiosurgery) allowed if no evidence of CNS progression for at least 4 weeks after completion of therapy
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hemoglobin at least 10.0 g/dL
• Hepatic
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• AST no greater than 2.5 times ULN
• Renal
• Creatinine no greater than 1.5 times ULN
• Other
• No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No prior hypersensitivity reaction to taxanes or other drugs formulated with polysorbate 80
• No grade 2 or greater peripheral neuropathy
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• At least 4 weeks since prior biologic therapy or immunotherapy
• No concurrent immunotherapy
• Chemotherapy
• See Disease Characteristics
• Prior chemotherapy (excluding gemcitabine) for radiosensitization allowed
• At least 4 weeks since prior chemotherapy
• At least 6 months since prior chemoembolization
• No prior chemotherapy for metastatic disease
• No other concurrent chemotherapy
• Endocrine therapy
• At least 4 weeks since prior hormonal therapy
• Radiotherapy
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy
• No prior radiotherapy to 25% or more of bone marrow
• No concurrent radiotherapy
• Surgery
• See Disease Characteristics